Delving into the Latest Updates on 武汉钧安制药有限公司 with Synapse

概览

关联

1

项与武汉钧安制药有限公司相关的药物

Zhenbing Koukuining Guccal Tablets

贞冰口溃宁含片

靶点-

作用机制-

在研机构-

原研机构-

在研适应症-

非在研适应症

复发性阿弗他溃疡

最高研发阶段无进展

首次获批国家/地区-

首次获批日期-

1

项与武汉钧安制药有限公司相关的临床试验

CTR20180834 / Completed临床2期

贞冰口溃宁含片治疗轻型复发性阿弗他溃疡的随机、双盲、安慰剂平行对照、多中心Ⅱ期临床试验

1）以安慰剂为对照，初步评价贞冰口溃宁含片治疗轻型复发性阿弗他溃疡（口疮-心脾积热证）的有效性和安全性。 2）探索贞冰口溃宁含片治疗轻型复发性阿弗他溃疡（口疮-心脾积热证）的合理剂量，为Ⅲ期临床试验提供依据

开始日期2019-05-16

申办/合作机构

武汉药谷科技开发有限公司

[+1]

100 项与武汉钧安制药有限公司相关的临床结果

登录后查看更多信息

0 项与武汉钧安制药有限公司相关的专利（医药）

登录后查看更多信息

1

项与武汉钧安制药有限公司相关的文献（医药）

2020-06-01·Current Medical Science4区 · 医学

Yu Gan Long Ameliorates Hepatic Fibrosis by Inhibiting PI3K/AKT, Ras/ERK and JAK1/STAT3 Signaling Pathways in CCl4-induced Liver Fibrosis Rats

4区 · 医学

Article

作者: Xu, Shi-Qing ; Ren, Hui-Ying ; Liu, Yan-Wen ; You, Peng-Tao ; Xia, Yu ; Quan, Tai-Min ; Tu, Yi-Jun ; Wang, Meng-Heng ; Song, Wan-Ci ; Li, Hou-Gang ; Cai, Yu ; Dan, Han-Xiong

Yu Gan Long (YGL) is a Chinese traditional herbal formula which has been reported to attenuate liver fibrosis for many years and we have explored its anti-fibrotic mechanism through blocking transforming growth factor (TGF-β) in the previous study. But the mechanisms associated with platelet-derived growth factor (PDGF)-BB remain obscure. In this study, we further investigated the mechanism of YGL reducing carbon tetrachloride (CCl₄)-induced liver fibrosis in rats. Our results showed that YGL suppressed CCl₄-induced upregulation of collagen IV (Col IV), type HI precollagen (PCHI), hyaluronuc acid (HA) and laminin (LN), which are implicated in liver fibrosis. Also, YGL reduced the α-smooth muscle actin (α-SMA) expression, which acts as the indicator of liver fibrosis. Furthermore, YGL decreased the serum levels of hepatic stellate cell (HSC) mitogen PDGF-BB and inflammation cytokines, including TNF-α, IL-1β, IL-6. Markers involved in liver fibrosis, such as Ras, p-Raf-1, p-ERK1/2, p-JNK, p-P38, p-PI3K, p-AKT, p-JAKl, p-STAT3 were downregulated significantly after treatment with YGL. Our results indicated that YGL ameliorated CCl₄-induced liver fibrosis by reducing inflammation cytokines production, and suppressing Ras/ERK, PI3K/AKT, and JAK1/STAT3 signaling pathways, which provided further evidence towards elucidation of the anti-fibrotic mechanism of YGL.

100 项与武汉钧安制药有限公司相关的药物交易

登录后查看更多信息

100 项与武汉钧安制药有限公司相关的转化医学

登录后查看更多信息